, 2005). Several randomized controlled studies have shown that naltrexone significantly reduces post-quit weight gain. A small preliminary study in 32 smokers found that naltrexone in combination learn more with nicotine patch suppressed weight gain compared to placebo alone (Krishnan-Sarin et al., 2003). Subsequently, King et al. (2006) conducted an 8-week placebo-controlled study of naltrexone (50 mg/day) combined with the nicotine patch with 110 subjects and found that participants in the naltrexone group gained significantly less weight (1.5 pounds) as compared to those in the placebo + nicotine patch group

(4.2 pounds). The largest clinical trial conducted to date was a dose ranging study of naltrexone (placebo, 25 mg, 50 mg, or 100 mg – taken daily) in combination with transdermal nicotine patch in 400 participants (O’Malley et al., 2006). The highest dose showed BIBW2992 cell line promise for promoting smoking abstinence, but effects on weight were not significant. In contrast, low-dose (25 mg/day) naltrexone significantly reduced post-cessation weight gain over 6 weeks, with participants showing an average weight gain of 1.5 pounds on this dose compared to 4.2 pounds for those taking placebo, although it did not increase smoking abstinence. Based on the weight gain findings, Toll et al. (2008) treated 20 weight-concerned smokers combining 25 mg naltrexone with 300 mg

bupropion SR, and showed that continuously abstinent participants in the naltrexone + bupropion group gained less weight (1.67 pounds) than those in a matched group of patients who received bupropion only (3.17 pounds; p = 0.35; Cohen’s d = 0.56) ( Toll et al., 2008). Consistent with these findings, a recent review concluded that naltrexone showed promise Unoprostone as a potential drug treatment for preventing post smoking cessation weight gain ( Parsons et al., 2009). Although naltrexone appears to reduce weight gain after quitting, effects on

smoking cessation have been inconclusive. Several studies showed that naltrexone did not help participants quit smoking or were mixed (Ahmadi et al., 2003, King et al., 2006, Toll et al., 2008 and Wong et al., 1999), whereas other studies showed that naltrexone may be beneficial for smoking cessation (Covey et al., 1999, Krishnan-Sarin et al., 2003 and O’Malley et al., 2006). Only the small pilot study by Toll et al. (2008) selected weight-concerned smokers. Prior studies tested short-term treatment from 4 to 8 weeks; whereas most smokers continue to gain weight over the first 6-months following smoking cessation (Hall et al., 1986, Klesges et al., 1997 and Pirie et al., 1992). In the present study, we tested the hypothesis that minimization of weight gain with low-dose naltrexone might translate to better quit outcomes for a population of weight-concerned smokers who believe that smoking helps control their weight.